We applied the revised clinical and biological (operationalized based on tau-PET) staging systems to participants in the large and deeply phenotyped BioFINDER-2 and Alzheimer Disease Neuroimaging Initiative (ADNI) cohorts, and examined the congruence or discrepancy between their clinical and biological stages. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.